Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634151 · ClinicalTrials.gov registry record · Phase 2
A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
A Phase 2 study, sponsored by NeuroBo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT02634151 is a Phase 2 study that has completed, run by NeuroBo Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT02634151, a Phase 2 study, has completed, sponsored by NeuroBo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of gemcabene 600 mg QD compared to placebo in patients with hypercholesterolemia not adequately controlled on high-intensity or moderate-intensity stable statin therapy. Patients with HeFH, ASCVD, or otherwise uncontrolled, may be included with baseline LDL-C value ≥ 100 mg/dL. Subjects were randomized 1:1 to gemcabene 600 mg once daily (QD) or placebo.
Interventions
- DRUG Placebo
- DRUG Gemcabene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02634151
The ClinicalTrials.gov registry entry for NCT02634151 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroBo Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02634151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02634151 about?
NCT02634151 is a clinical study titled "A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins". The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of gemcabene 600 mg QD compared to placebo in patients with hypercholesterolemia not adequately controlled on high-intensity or moderate-intensity stable statin therapy. Patients with HeFH, ASCVD, or oth...
What is the current status of trial NCT02634151?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2016-11. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02634151?
The interventions under investigation include: Placebo (DRUG), Gemcabene (DRUG).
Who is sponsoring clinical trial NCT02634151?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.